Epigenetic effects of cannabis: A systematic scoping review of behavioral and emotional symptoms associated with cannabis use and exocannabinoid exposure

Data de publicação: Data Ahead of Print:

Autores da FMUP

  • Maria Augusta Vieira Coelho

    Autor

Participantes de fora da FMUP

  • Machado, Ana Sofia
  • Braganca, Miguel

Unidades de investigação

Abstract

Background: Recent research suggests that epigenetic modifications may mediate the behavioral effects of cannabis, influencing exocannabinnoids' long term effects in cognitive function and its role in the emergence of psychotic symptoms. Basic procedures: In this systematic scoping review, we assessed the current evidence of epigenetic effects associated with the use of cannabis or exocannabinoid administration and their relationship with behavioral and emotional symptoms. We searched PubMed, Cochrane CENTRAL, and Web of Science, up to January 2022, using the terms ``cannabis'' and ``epigenetics.'' The search yielded 178 articles, of which 43 underwent full article revision; 37 articles were included in the review. Main findings: The gathered evidence included observational cross-sectional studies conducted on human subjects and experimental designs using animal models that conveyed disparity in administration dosage, methods of cannabis use assessment and targeted epigenetic mechanisms. Nine studies performed epigenome-wide analysis with identification of differentially methylated sites; most of these studies found a global hypomethylation, and enrichment in genes related to cellular survival and neurodevelopment. Other studies assessed methylation at specific genes and found that cannabis exposure was associated with reduced methylation at Cg05575921, DNMT1, DRD2, COMT, DLGAP2, Arg1, STAT3, MGMT, and PENK, while hypermethylation was found at DNMT3a/b, NCAM1, and AKT1. Conclusions: The review found evidence of an exocannabinoid-induced epigenetic changes that modulate depressive-anxious, psychotic, and addictive behavioural phenotypes. Further studies will require dosage exposure/administration uniformization and a customized pool of genes to assess their suitability as biomarkers for psychiatric diseases.

Dados da publicação

ISSN/ISSNe:
0376-8716, 1879-0046

Drug and Alcohol Dependence  Elsevier Ireland Ltd

Tipo:
Article
Páginas:
-
Link para outro recurso:
www.scopus.com

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • Cannabis; Epigenetic effect; Behavioral; Emotional; Exocannabinoid exposure

Proyectos asociados

Mind the gap: An insight into the temporal relationship between initiation of cannabis use and onset of psychosis

Investigador Principal: Maria Augusta Vieira Coelho

Estudo Clínico Académico . 2022

Plasma levels of oleoylethanolamide in patients with feeding and eating disorders

Investigador Principal: Maria Augusta Vieira Coelho

Estudo Clínico Académico . 2022

Perceção do risco associado ao uso de drogas em doentes com história prévia de psicose induzida por cannabis

Investigador Principal: Maria Augusta Vieira Coelho

Estudo Clínico Académico . 2022

Ongoing Clinical Trials with Monoclonal Antibodies in Schizophrenia

Investigador Principal: Maria Augusta Vieira Coelho

Estudo Clínico Académico . 2020

Impulsivity and Its Relationship With Lisdexamfetamine Dimesylate Treatment in Binge Eating Disorder

Investigador Principal: Maria Augusta Vieira Coelho

Ensaio Clínico Académico (Eating Disorder) . 2022

Effect of the COVID-19 pandemic in patients with Obsessive-Compulsive Disorder

Investigador Principal: Maria Augusta Vieira Coelho

Estudo Clínico Académico . 2022

The role of opicapone for the treatment of patients with Parkinson´s Disease: clinical evidence

Investigador Principal: Maria Augusta Vieira Coelho

Estudo Clínico Académico . 2023

O Sistema Endocanabinoide na Patofisiologia da Fibrose Dérmica

Investigador Principal: Maria Augusta Vieira Coelho

Estudo Clínico Académico . 2021

Citar a publicação

Partilhar a publicação